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Background: Dose selection is an important step in pharmacokinetic (PK) studies of hemodialysis patients.
We propose a simulation-based dose-selection method for PK studies of hemodialysis patients using a
subpharmacological dose of oseltamivir as a model drug.
Methods: The concentrations of oseltamivir and its active metabolite, oseltamivir carboxylate (OC), were measured
by liquid chromatography-tandem mass spectrometry. To determine a low oseltamivir dose exhibiting PK linearity,
a pilot low dose determination investigation (n = 4) was performed using a single administration dose-escalation
study. After the dose was determined, a low dose study (n = 10) was performed, and the optimal dose required to
reach the hypothetical target OC exposure (area under the concentration-time curve [AUC] of 60,000 ng · hr/mL)
was simulated using a nonparametric superposition method. Finally, observed PKs at the optimal dose were
compared to the simulated PKs to verify PK predictability.
Results: In the pilot low dose determination study, 2.5 mg of oseltamivir was determined to be the low dose.
Subsequently, we performed a single-dose PK study with the low oseltamivir dose in an additional group of 10
hemodialysis patients. The predicted AUClast of OC following continuous oseltamivir doses was simulated, and
35 mg of oseltamivir corresponded to the hypothetical target AUClast of OC. The observed PK profiles of OC at a
35-mg oseltamivir dose and the simulated data based on the low dose study were in close alignment.
Conclusion: The results indicate that the proposed method provides a rational approach to determine the proper
PK dose in hemodialysis patients.
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In addition to impaired renal function, hemodialysis pa-
tients may also possess altered pharmacokinetics (PKs)
caused by hemodialysis itself. Hemodialysis is an import-
ant drug elimination rout, which is influenced by the
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reproduction in any medium, provided the orof dialysis [1]. In addition, hemodialysis may influence
the metabolic clearance of a drug by affecting drug-
metabolizing enzymes or transporters [2]. However, des-
pite the difficulty of predicting PKs, which results from
various interfering factors, previous PK studies have
often excluded the hemodialysis patient population [3,4].
One reason for frequent exclusion is the uncertainty of
selecting proper dosing for a PK study. In fact, improper
dosing during PK studies can cause several problems.
For example, administration of a potentially unsafe high
dose during a PK study may lead to drug accumulation
and adverse drug reactions, particularly in hemodialysis. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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may lead to unnecessary PK study repetition. Therefore,
our objective was to develop a dose selection method for
PK studies in hemodialysis patients using the simulation-
extrapolation of an optimal PK dose from the PK parame-
ters of a subpharmacological dose.
In this study, we chose oseltamivir as a model drug to
evaluate this proposed method because PKs of its active
metabolite, oseltamivir carboxylate (OC), were dramatic-
ally altered, especially in patients undergoing hemodialysis
[5]. Orally administered oseltamivir is rapidly converted
into OC by first pass metabolism, which is minimally af-
fected by liver function [6]. Consequently, approximately
80% of orally administered oseltamivir reaches the sys-
temic circulation as OC, and plasma OC concentrations
exhibit minimal inter- and intra-subject variability [7].
The excretion of OC occurs exclusively via the kidneys,
and therefore, OC exposure is substantially increased in
patients with end-stage renal disease (ESRD) [7,8]. In
addition, hemodialysis may also affect the PKs of oselta-
mivir because a significant fraction of OC is removed by
hemodialysis [5,7]. Moreover, clinical concerns have
arisen regarding oseltamivir use in patients with ESRD
because of their high mortality from influenza, generally
severe courses of influenza infection, and reduced re-
sponse to vaccinations [9]. These PK and clinical char-
acteristics of oseltamivir correspond to a drug category
where the U.S. FDA recommends mandatory PK studies
in patients with impaired renal function [10]. Therefore,
we selected oseltamivir, even though this drug is already
approved for mass marketing and its therapeutic dose
PKs in ESRD patients are well known [5].
Methods
This study was conducted at the Clinical Trials Center
and Dialysis Unit of Seoul National University Hospital
(Seoul, Korea) from March 2011 to March 2012. The In-
stitutional Review Board and the Korean Food and Drug
Administration approved the study protocol. All proce-
dures were performed in accordance with the recom-
mendations of the Declaration of Helsinki. All subjects
provided written informed consent and received pro-
rated compensation after the study.
Study subjects
Eligibility criteria were an age >20 years and anuric non-
diabetic ESRD undergoing intermittent hemodialysis. Ex-
clusion criteria included current pregnancy or lactation,
the prior use of an antiviral agent within the past three
months, a history of allergic reaction to oseltamivir, alco-
hol and/or drug abuse, and participation in any other clin-
ical study within two months prior to the present study.
Additionally, subjects with gastrointestinal disease that
could alter drug absorption were also excluded from thestudy. All other medications except anti-hypertensives
were prohibited from three days prior to oseltamivir ad-
ministration to the end of the study. As a safety precau-
tion, subjects underwent a screening evaluation, including
a medical history, vital signs, 12-lead electrocardiography,
and clinical laboratory tests (complete blood count and
serum chemistry profiles) that were performed within
4 weeks of oseltamivir administration. Subjects were
fasted 8 hr prior and 4 hr following oseltamivir adminis-
tration. During the admission period, subjects received
and ate only the standard food and drink provided by
the clinical trials center and were not allowed to con-
sume fruit juice or any beverage containing alcohol or
caffeine. All observed or self-reported adverse events
that occurred over the study period were recorded.
Blood pressure, pulse rate, and body temperature were
measured at each sampling time.
Study design
Step 1: pilot low dose determination study
The dose-finding step was designed as an open-label, sin-
gle sequence dose escalation, single-dosing study to deter-
mine the lowest oseltamivir dose detectable in plasma by
liquid chromatography-tandem mass spectrometry (LC-
MS/MS) and showing dose-linearity with two higher osel-
tamivir doses. A total of four hemodialysis patients were
enrolled in this pilot study. Considering the lower limit of
quantification (LLOQ) for plasma oseltamivir concentra-
tions (0.2 ng/mL) by LC-MS/MS as well as the oseltamivir
PKs in patients with advanced renal dysfunction not on
dialysis [7], a 2.5-mg oseltamivir dose was expected as the
lowest detectable dose. The PK studies were performed
using 3-week wash-out periods with dose doubling until
the PK parameters at certain doses exhibited dose-
linearity with the PK parameters of two higher doses.
All procedures were identical in all periods except for
the dose administered. All patients were dialyzed for
4 hr using a high-flux membrane (Polyflux 170H;
Gambro, Lund, Sweden; ultrafiltration coefficient, 70 mL/
hr/Kg; single use). Blood flow was maintained at a con-
stant rate of 250 mL/min, and the dialysate flow rate was
also held constant at 500 mL/min.
Step 2: low dose PK study and extrapolation of the
appropriate PK dose
After determining the low oseltamivir dose during the
pilot study, an additional set of 10 hemodialysis patients
were evaluated in a single dose standard PK study using
the low oseltamivir dose. Subsequently, the predicted area
under the concentration-time curve (AUC) from drug ad-
ministration to 72 hr post-administration or to the last
measurable time point (AUClast) of OC following continu-
ous doses up to 150 mg was simulated from the low dose
data using a nonparametric superposition method with
Table 1 Demographic data for study subjects
Low dose
determination
pilot study (n = 4)
Low dose study
and method
validation (n = 10)
Age (yr) 56.8 (14.8) 52.4 (14.2)
Sex (male: female) 2:2 6:4
Dry weight (Kg) 50.3 (13.4) 52.9 (12.1)
Body mass index (kg/m2) 20.6 (5.0) 20.1 (3.0)
Cause of ESRD (n)
Chronic glomerulonephritis 2 4
Hypertension 1 3
Unknown 1 3
Time on hemodialysis 3.3 (0.8) 4.1 (1.6)
Hemoglobin (g/dL) 10.50 (0.58) 10.88 (0.92)
Dialysis efficiency
(at 44–48 hr of study period)
Single-pool Kt/VUrea 1.47 (0.10) 1.58 (0.28)
Urea reduction ration (%) 70.7 (2.1) 73.5 (5.3)
Ultrafiltration rate
(L/session)
2.60 (0.13) 2.10 (0.76)
Data presented mean (standard deviation) or numbers.
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ation, Mountain View, CA, USA). Based on the results
of a previous oseltamivir PK study in hemodialysis pa-
tients [5], a hypothetical target AUClast of OC was de-
fined as 60,000 ng · hr/mL, and the oseltamivir dose
required to reach this target was considered to be the
optimal PK dose.
Step 3: method validation
To validate the dose-selection method, the same partici-
pants were evaluated in a PK study using the extrapo-
lated dose after a 3-week wash-out period. The observed
PKs were compared to the simulated PKs based on the
low dose study. The simulations for plasma oseltamivir,
plasma OC, and dialysate OC after the administration of
the extrapolated oseltamivir dose were performed using
a nonparametric superposition method with the WinNo-
lin® version 6.3 software.
PK assessment
The study subjects received a solution containing oselta-
mivir dissolved in 20 mL of purified water followed by
the administration of 150 mL of water immediately after
the completion of hemodialysis. Blood samples were col-
lected before oseltamivir administration and at 1, 1.5, 2,
2.5, 3, 6, 12, 24, 44 (dialysis start), 48 (dialysis end), and
72 hr after oseltamivir administration through an in-
dwelling catheter or direct venipuncture into pre-cooled
fluoride tubes (BD, Franklin Lakes, NJ, USA). Plasma
was separated from blood by centrifugation at 4°C within
2 hr of collection. Dialysate was also collected hourly dur-
ing the dialysis. All samples were stored at −70°C until
further use.
Determination of plasma and dialysate oseltamivir and
OC concentrations
Oseltamivir, OC, and their trideuterated species used as
internal standards were kindly provided by Hoffmann-La
Roche (Basel, Switzerland). The quantification of plasma
and dialysate oseltamivir and OC were performed using
an Agilent 6460 triple quadrupole mass spectrometer
(Palo Alto, CA, USA) coupled to an Agilent 1260 LC
system (Palo Alto) using oseltamivir d3-carboxylate as
an internal standard. The LLOQ were determined from
standard curves of oseltamivir (0.2-100 ng/ml) and OC
(2–500 ng/mL). The LLOQ was 0.2 ng/ml for oseltami-
vir and 2 ng/mL for OC. The coefficients of determin-
ation of the calibration curves were all >0.99. Standard
curves were accurate (93.7% ≤% accuracy ≤101.2%) and
precise (0.775% ≤% precision ≤6.924%) across a range of
0.5 to 80 ng/mL for oseltamivir and were accurate
(98.8% ≤% accuracy ≤103.5%) and precise (1.032% ≤%
precision ≤2.857%) across a range of 5 to 400 ng/mL
for OC.PK and statistical analyses
The PK parameters were calculated by a non-com
partmental method using Phoenix®. The AUClast was
computed using the linear trapezoidal approximation
method. The maximum observed plasma concentration
(Cmax) and time to reach Cmax (Tmax) were directly de-
termined from the individual concentration–time pro-
files. The oral plasma clearance (CL/F) was calculated as
the dose/AUClast. Intradialytic oseltamivir and OC clear-
ance were calculated using the recovery method and the
following equation: CLHD = R/AUCHD, where CLHD is
the oseltamivir or OC clearance through hemodialysis, R
is the amount of oseltamivir or OC recovered during the
dialysis session, and AUCHD is the area under the serum
concentration-time curve during hemodialysis.
The Kruskal-Wallis test was used to compare the dose-
normalized Cmax and AUClast between doses of oseltami-
vir. The dose proportionality in the dose-finding pilot
study was tested using a power model analysis of log-
transformed PK parameters versus the log-transformed
dose. Dose proportionality was assumed if the slope was
not statistically significantly different from unity and the
95% confidence interval (CI) included 1.0 [11]. The
extrapolated dose of oseltamivir was simulated using
nonparametric superposition (WinNolin® version 6.3
software), which can be used to predict drug concentra-
tions after multiple dosing at steady state, based on
non-compartmental results of single dose data and not
assuming any PK model [12].
Figure 1 Semi-log plots of the dose-normalized mean plasma oseltamivir (A), plasma oseltamivir carboxylate (B), and dialysate
oseltamivir carboxylate (C) concentrations following a single oral dose of 2.5 (○), 5.0 (●), and 10.0 mg (■) of oseltamivir. Error bars
represent the standard deviation. OC, oseltamivir carboxylate.
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means (SD). SPSS (version 12.0; SPSS Korea, Seoul,
Korea) was used for the statistical analyses, and a




The demographic characteristics of the study partici-
pants are listed in Table 1. No subjects exhibited adverse
events after oseltamivir administration in the dose-finding
pilot study. However, two of the 10 participants who re-
ceived a dose of 35 mg of oseltamivir experienced nausea,
which was mild in intensity. No serious adverse events oc-
curred during the study period.
Pharmacokinetics
Pilot low dose determination study
Figure 1 shows a semi-log plot of the mean plasma osel-
tamivir, plasma OC, and dialysate OC concentrations
normalized to a 1-mg oseltamivir dose versus time postTable 2 Pharmacokinetic parameters of oseltamivir and oselt








Cmax (ng/mL) 1.81 (0.92) 4.68 (3.28) 8.40
Tmax (hr) 1.00 [1.00, 1.55] 1.06 [1.00, 1.13] 1.00 [1.0
AUClast (ng h/mL) 3.24 (0.81) 9.60 (6.83) 15.47
AUCHD (ng h/mL) NA NA N
CL/F (L/hr) 554.41 (37.86) 558.27 (252.14) 645.73
CLHD (mL/hr) NA NA N
Drug excreted by dialysis (%)* NA NA N
Data presented mean (SD) except Tmax, median [min, max]; Cmax, peak plasma conc
curve; CL/F, oral plasma clearance; CLHD, dialysis clearance; NA, not applicable;
*amoadministration of a single oral oseltamivir dose of 2.5, 5.0,
and 10.0 mg. Although oseltamivir could not be detected
after 6 hr, the shapes of the oseltamivir and OC dose re-
sponse curves were similar, and the curves were predom-
inantly superimposable at the various doses. Similarly, the
mean AUClast values of oseltamivir and OC, and the
AUCHD of OC increased in a dose-dependent manner
(Table 2). Additionally, no differences were detected
between groups with respect to the dose-normalized
Cmax and AUClast using the Kruskal-Wallis test (Table 3).
Furthermore, power model analysis displayed dose-
proportional increases in the AUClast and Cmax of osel-
tamivir and OC within a dose range of 2.5 to 10 mg.
The slope estimates were close to unity for the AUClast
and Cmax of oseltamivir and OC and AUCHD of OC. All
the corresponding 95% CIs included 1.0 (Table 4).
Together, the dose relationships of AUClast and Cmax for
oseltamivir and OC within the 2.5 to 10 mg dose range
did not deviate from dose proportionality. Accordingly,
the subsequent PK study was performed with an oral dose










(3.03) 181.07 (96.38) 410.35 (206.54) 599.23 (360.64)
0, 1.55] 44.11 [24.00, 44.25] 43.99 [24.0, 44.05] 24.01 [24.00, 43.68]
(5.48) 7697.12 (3930.52) 12497.57 (3537.45) 25394.42 (12912.41)
A 288.52 (119.78) 458.82 (226.88) 784.87 (205.39)
(161.19) NA NA NA
A 5.14 (1.87) 6.41 (3.43) 6.92 (1.30)
A 0.06 (0.04) 0.05 (0.02) 0.04 (0.01)
entration; Tmax, time to Cmax; AUC, area under the plasma concentration–time
unt excreted of oseltamivir carboxylate / administered oseltamivir.
Table 3 Dose-normalized Cmax and AUClast following a single oral administration of 2.5, 5, and 10 mg of oseltamivir
Parameter Oseltamivir P-value* Oseltamivir carboxylate P-value*
Oseltamivir
2.5 mg (n = 4)
Oseltamivir
5 mg (n = 4)
Oseltamivir
10 mg (n = 4)
Oseltamivir
2.5 mg (n = 4)
Oseltamivir
5 mg (n = 4)
Oseltamivir
10 mg (n = 4)
Cmax/dose (ng/mL/mg) 0.72 (0.37) 0.94 (0.66) 0.84 (0.30) 0.981 72.43 (38.55) 82.07 (41.31) 59.92 (36.06) 0.926
AUClast/dose (ng · h/mL/mg) 1.29 (0.33) 1.92 (1.37) 1.55 (0.55) 0.981 3078.9 (1572.2) 2499.5 (707.5) 2539.4 (1291.2) 0.944
Data presented mean (SD); Cmax, peak plasma concentration; AUC, area under the plasma concentration–time curve;
*The Kruskal-Wallis test.
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PK dose
After a low oseltamivir dose of 2.5 mg was determined,
we performed a single-dosing standard PK study follow-
ing the administration of 2.5 mg of oseltamivir with 10
additional hemodialysis patients. The mean Cmax of osel-
tamivir and OC were 1.63 ± 0.87 and 128.14 ± 50.41 ng/
mL, respectively, and the median Tmax of oseltamivir
and OC were 1.00 (0.98-1.00) and 33.95 (12.00-44.08) hr,
respectively. The AUClast values of oseltamivir and OC
were 2.55 ± 1.17 and 5604.11 ± 2097.22 ng · hr/mL, re-
spectively. The CL/F of oseltamivir was 618.84 ± 424.92 L/
hr, and the CLHD of OC was 7.07 ± 4.30 mL/hr. Subse-
quently, the predicted AUClast values of OC following
continuous doses were simulated from the low dose data
using a nonparametric superposition method (Figure 2).
The appropriate oral PK oseltamivir dose was determined
to be 34.61 mg, which corresponded to the hypothetical
target AUClast of 60,000 ng · hr/mL.Method validation
The comparisons of the observed concentration–time
profiles of plasma oseltamivir, plasma OC, and dialysate
OC at 35 mg of oseltamivir (rounded up from 34.61 mg)
and the simulated data based on the PK parameters at a
dose of 2.5 mg are shown in Figure 3. The simulated
curves correspond closely to the measured values, indi-
cating that low dose PK studies can be used to predict
the proper PK dose in hemodialysis patients.Table 4 Power model analysis for dose-concentration
relationship
Parameters Estimate of β 95% CI
Oseltamivir
Cmax (ng/mL) 1.187 0.556-1.818
AUClast (ng h/mL) 1.121 0.652-1.591
Oseltamivir carboxylate
Cmax (ng/mL) 0.889 0.232-1.547
AUClast (ng h/mL) 0.897 0.374-1.421
AUCHD (ng h/mL) 1.062 0.507-1.617
Cmax, peak plasma concentration; CI, confidence interval; AUC, area under the
plasma concentration–time curve.Discussion
Although current guidelines recommend conducting a PK
study for all investigational drugs that are likely be used in
ESRD patients [10,13-15], only a small proportion of
drugs have been evaluated for PKs in this population. For
example, fewer than 30% of the new molecular entities ap-
proved by the U.S. FDA between 2003 and 2007 have had
their PK profiles assessed in hemodialysis patients during
drug development [4]. Moreover, PK studies evaluating
drug efficacy and safety, which are usually conducted in
phase 3 clinical trials, frequently exclude the hemodialysis
patient population [3]. Accordingly, this paucity of PK
studies may lead to non-optimized pharmacotherapies
and medication-related problems, including drug dosing
errors and inadequate efficacy [16]. In addition, the ma-
jority of the previously published PK data potentially
underestimate the effects of dialysis on drug elimination
because recently introduced dialyzers with high perme-
ability and large surface areas were not examined [17-20].
Therefore, PK analyses for many drugs, some of which are
already marketed, are necessary to optimize drug dosing
in hemodialysis patients.
Individualized dosing recommendations that account
for renal function can be derived from the estimation of
PKs either through a simulation from detailed PK ana-
lyses in patients with varying degrees of renal function
or a mixed-effect modeling approach using population-
based PK parameters obtained in large clinical studies
[1]. However, given the impact of hemodialysis on drug
PKs, PK profiles in this patient population cannot simply
be extrapolated from the data of pre-dialysis patients
with kidney disease [3]. Indeed, hemodialysis may not only
eliminate a drug or its active metabolites but can also alter
the PK through increased metabolic clearance through the
dialysis-induced removal of endogenous inhibitors of
metabolic enzymes [2]. Additionally, hemodialysis may de-
crease the intercompartmental drug clearance [19]. There-
fore, standard PK studies in hemodialysis patients should
be mandatory because of these dialysis-associated PK
perturbations.
Dose selection in PK studies for hemodialysis patients
may be an important practical step, and currently, U.S.
FDA guidelines recommend using the same dose for all
patients in renal impairment-PK studies regardless of the
degree of renal function, because the peak concentration
Figure 2 Predicted AUClast of plasma oseltamivir carboxylate
following continuous doses simulated from the low dose data
with a nonparametric superposition method. The solid and
dotted lines represent the fitted line and standard error, respectively.
OC, oseltamivir carboxylate.
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ever, in case of drugs with extensive renal excretion, such
as oseltamivir, exposure to a drug or its active metabolites
may be increased more than 10-fold in patients with se-
vere renal impairment when an unadjusted dose is admin-
istered [7]. Moreover, approximately 70% of hemodialysis
patients lose residual renal function within 1 year after the
initiation of hemodialysis [21] and thus the majority of
hemodialysis patients do not have residual renal function.
Therefore, drug accumulation and adverse drug reactions
during PK studies may be more prominent in these pa-
tients. In contrast, the selection of a sub-efficacious dose
may cause unnecessary repetitious PK studies, thereby in-
creasing study cost and duration. Therefore, a rational ap-
proach for dose selection that considers both safety and
efficacy should precede the standard PK study, especially
for drugs with renal excretion and low therapeutic range.
In the present study, we employed oseltamivir as a model
drug and demonstrated that PK profiles at therapeuticFigure 3 Simulated (red) and observed (black) concentration-time pro
(B), and dialysate oseltamivir carboxylate (C) concentrations. OC, oseltdoses may be predicted using PK modeling and simulation
based on low dose PK data. This finding suggests that low
dose PK studies are useful in determining the dose used in
detailed PK studies in hemodialysis patients. However,
considerable debate exists regarding the prediction of the
optimal PK dose from low dose studies because of the
possibility of PK non-linearity between the doses. Indeed,
the extrapolated prediction of the clinical PK parameters
from a low dose study may not be accurate if a drug ex-
hibits dose-dependent non-linear PKs [22]. To minimize
the non-linearity concern, we performed a dose-escalation
PK study in a small number of patients to select a low
dose that exhibits linear PKs with two higher doses.
Although micro-dosing PK studies using less than
100 μg of a drug can avoid toxicological effects [23], this
approach requires expensive and specialized method-
ologies, such as positron emission tomography and ac-
celerator mass spectrometry that require radioactive
carbon-labeled drugs [24]. In addition, although many
comparative studies for various drugs have shown PK
linearity between the micro-dose and therapeutic dose
[25-28], micro-dosing studies may not always accurately
predict the PK parameters at higher therapeutic doses
[29-31]. This non-linearity may arise from the non-linear
disposition of a drug as well as the saturation of metabolic
enzymes or drug transporters [32,33]. Therefore, the valid
prediction of pharmacokinetics at therapeutic doses may
be further complicated in micro-dosing studies in ESRD
patients because impaired drug metabolism and dysfunc-
tion of drug transporters in patients with ESRD can alter
non-renal clearance of drugs [34,35]. Thus, PK studies
using non-radio-labeled drugs at low doses exhibiting lin-
ear pharmacokinetics with higher doses may present an
alternative and simpler method to determine the PKs of a
drug while avoiding unsafe higher doses.
The present study has several limitations that need to
be addressed. First, the inter-compartmental clearance
was not assessed. Second, the characteristics of OC re-
bound after dialysis were not fully assessed because nofiles of plasma oseltamivir (A), plasma oseltamivir carboxylate
amivir carboxylate.
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bound quantitatively, further study should be conducted
in HD patients using extended sampling time points.
Conclusions
In conclusion, the present study suggests that the proper
PK drug dose for hemodialysis patients can be simulated
from the PK parameters generated after the administra-
tion of a low dose at which adverse drug reactions are
avoided.
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